BioSpace News Archive

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the treatment of the first patient in the second cohort of the Phase 1 dose-escalation trial evaluating the safety and tolerability of FX201, an investigational, intra-articular, IL-1Ra gene therapy product candidate being developed for the treatment of osteoarthritis (OA).

Champions Oncology, Inc., engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, announced it will report its financial and operational results for the first quarter ended July 31, 2020, on Monday, September 14, 2020, after market close.

Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced its participation at the 22nd Annual H.C. Wainwright Global Investment Conference.

CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 18th Annual Morgan Stanley Global Healthcare Conference

Ambu Inc., the world leader in single-use endoscopes, announced today that it has been awarded a contract with UroGPO, the largest Group Purchasing Organization for urology private practice clinics in the U.S.

NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, announced today that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate the safety and tolerability of SNK01,

Proteros will build a leading Center of Excellence for industrial cryo-EM applications to improve success rates in drug discovery

ANANDA Scientific Inc., a biotech pharma company, announced that Sohail Zaidi has been appointed as ANANDA’s new President.

First CAR T therapy leveraging combination of cell intrinsic PD1DNR checkpoint inhibition and 1XX CAR signaling technologies to enter the clinic

Announces Decision to Fund Clinical Manufacture of Ficlatuzumab for Potential Phase 3 Study and Update to Biodesix Partnership